Aastrom downgraded to Sell from Neutral at Roth Capital Roth Capital downgraded Aastrom to Sell with a 25c price target after the company said it will stop enrollment and end the Phase 3 REVIVE clinical trial in patients with critical limb ischemia.
News For ASTM From The Last 14 Days
Check below for free stories on ASTM the last two weeks.
Aastrom announces definitive agreement to acquire Sanofi's CTRM business Aastrom Biosciences (ASTM) announced that it has entered into a definitive agreement to acquire Sanofi's (SNY) Cell Therapy and Regenerative Medicine, or CTRM, business for a purchase price of $6.5M, with $4M payable in cash at closing and $2.5M payable in the form of a promissory note. The acquisition is subject to customary closing conditions and is scheduled to close in approximately three weeks. Through the CTRM acquisition, Aastrom is acquiring global commercial rights to three marketed autologous cell therapy products. Aastrom will also acquire global manufacturing and production centers located in the United States and Denmark.